21 – 30 of 89
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [18F]flutemetamol amyloid PET images
Bucci, Marco ; Savitcheva, Irina ; Farrar, Gill ; Salvadó, Gemma ; Collij, Lyduine ; Doré, Vincent ; Gispert, Juan Domingo ; Gunn, Roger ; Hanseeuw, Bernard and Hansson, Oskar LU
, et al.
(2021)
In European Journal of Nuclear Medicine and Molecular Imaging
48(7).
p.2183-2199
- Contribution to journal › Article
-
Mark
Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimer’s disease in the context of a structured 5-phase biomarker development framework
Wolters, E. E. ; Dodich, A. ; Boccardi, M. ; Corre, J. ; Drzezga, A. ; Hansson, O. LU
; Nordberg, A.
; Frisoni, G. B.
; Garibotto, V.
and Ossenkoppele, R.
LU
(2021)
In European Journal of Nuclear Medicine and Molecular Imaging
48(7).
p.2097-2109
- Contribution to journal › Scientific review
-
Mark
Differential associations of APOE-ε2 and APOE-ε4 alleles with PET-measured amyloid-β and tau deposition in older individuals without dementia
- Contribution to journal › Article
-
Mark
The impact of demographic, clinical, genetic, and imaging variables on tau PET status
Ossenkoppele, Rik LU ; Leuzy, Antoine LU ; Cho, Hanna ; Sudre, Carole H. ; Strandberg, Olof LU ; Smith, Ruben LU ; Palmqvist, Sebastian LU
; Mattsson-Carlgren, Niklas
LU
; Olsson, Tomas
and Jögi, Jonas
LU
, et al.
(2021)
In European Journal of Nuclear Medicine and Molecular Imaging
48(7).
p.2245-2258
- Contribution to journal › Article
-
Mark
The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers
Ashton, N. J. ; Leuzy, A. LU ; Karikari, T. K. ; Mattsson-Carlgren, N. LU
; Dodich, A.
; Boccardi, M.
; Corre, J.
; Drzezga, A.
; Nordberg, A.
and Ossenkoppele, R.
LU
, et al.
(2021)
In European Journal of Nuclear Medicine and Molecular Imaging
48(7).
p.2140-2156
- Contribution to journal › Scientific review
-
Mark
2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
Leuzy, A. LU ; Ashton, N. J. ; Mattsson-Carlgren, N. LU
; Dodich, A.
; Boccardi, M.
; Corre, J.
; Drzezga, A.
; Nordberg, A.
; Ossenkoppele, R.
LU
and Zetterberg, H.
LU
, et al.
(2021)
In European Journal of Nuclear Medicine and Molecular Imaging
48(7).
p.2121-2139
- Contribution to journal › Scientific review
-
Mark
The strategic biomarker roadmap for the validation of Alzheimer’s diagnostic biomarkers : methodological update
- Contribution to journal › Article
-
Mark
EANM position paper on article 56 of the Council Directive 2013/59/Euratom (basic safety standards) for nuclear medicine therapy
- Contribution to journal › Article
- 2020
-
Mark
Spatial patterns of tau deposition are associated with amyloid, ApoE, sex, and cognitive decline in older adults
(2020) In European Journal of Nuclear Medicine and Molecular Imaging
- Contribution to journal › Article
-
Mark
Letter to editor
- Contribution to journal › Debate/Note/Editorial